澳大利亚10,392剂带状疱疹疫苗上市后监测
该研究分析澳大利亚SmartVax主动监测系统2021年6月1日至2022年5月31日≥50岁人群接种带状疱疹疫苗的数据,共10,392条记录(ZVL 8,341条;HZ/su 2,051条)。HZ/su报告不良事件的比例高于ZVL,校正人口学变量后HZ/su报告不良事件的比值比为6.44(95%CI:5.57-7.46)。仅59剂(0.6%)因不良事件就医,作者认为多数不良事件轻微,支持疫苗推荐转向HZ/su。
要点
- HZ/su报告任何不良事件的比例为41.9%,高于ZVL的8.7%。
- 校正后HZ/su报告不良事件的比值比为6.44(95%CI:5.57-7.46),高于ZVL。
- 仅59剂(0.6%)因不良事件就医,多数不良事件轻微。
核心结论
- HZ/su报告不良事件的比例高于ZVL,但多数不良事件轻微且无需就医,作者认为研究结果支持疫苗推荐转向HZ/su并用于免疫规划。
研究设计与样本
- 分析SmartVax主动监测系统2021年6月1日至2022年5月31日期间≥50岁人群接种ZVL或HZ/su的免疫记录,共10,392条(ZVL 8,341条;HZ/su 2,051条),采用多变量逻辑回归比较不良事件报告比例。
主要发现
- HZ/su报告任何不良事件的比例为41.9%,ZVL为8.7%。
- HZ/su报告局部不良事件的比例为33.8%,ZVL为6.2%。
- HZ/su报告全身不良事件的比例为25.2%,ZVL为3.5%。
- 校正人口学变量后,HZ/su报告不良事件的比值比为6.44(95%CI:5.57-7.46),高于ZVL。
- 仅59剂(0.6%)因不良事件就医。
关键数值与推荐
- 带状疱疹免疫推荐用于≥50岁成人。
- 澳大利亚可用的两种疫苗为减毒活疫苗(ZVL,Zostavax®)和佐剂重组亚单位疫苗(HZ/su,Shingrix®)。
- 免疫指南因HZ/su在预防带状疱疹及相关并发症方面效力更高而正将推荐转向HZ/su。
临床怎么用
- 作者认为研究结果支持疫苗推荐转向HZ/su并用于免疫规划。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Immunisation against herpes zoster is recommended for adults aged ≥ 50 years. Two vaccines, a live attenuated (ZVL, Zostavax®) and an adjuvant recombinant subunit (HZ/su, Shingrix®), are available in Australia. Immunisation guidelines are shifting their recommendations towards HZ/su because of higher efficacy in preventing herpes zoster and associated complications. However, there are limited post-marketing data comparing the safety profiles of these vaccines. METHODS: Data from SmartVax, an active surveillance system for monitoring adverse events following immunisation (AEFIs) utilised by > 450 clinics throughout Australia, were analysed. Data from patients aged ≥ 50 years, who received ZVL or HZ/su, from 1 June 2021 to 31 May 2022, at clinics that utilised SmartVax were included. The proportion of records where patients who reported any, local, and systemic AEFIs after receiving ZVL or HZ/su were compared using multivariable logistic regression models. RESULTS: Data from 10,392 immunisation records (n = 8341 ZVL; n = 2051 HZ/su) were included. The proportion of AEFIs reported was higher with HZ/su (41.9 % [any], 33.8 % [local], 25.2 % [systemic]) than with ZVL (8.7 % [any], 6.2 % [local], 3.5 % [systemic]). After controlling for demographic variables, HZ/su presented a 6-fold increase in the odds (OR 6.44; 95 %CI: 5.57-7.46) of a reported AEFI compared to ZVL. Only 59 (0.6 %) of vaccinations lead to medical attention being sought due to an AEFI. CONCLUSIONS: While rates of AEFIs was higher with HZ/su than ZVL, most AEFIs were mild and did not require medical attention. Our findings support the change in vaccine recommendations and the use of HZ/su in immunisation programs.
引用
- Muttucumaru R, Lau CL, Leeb A, et al. Post-marketing surveillance of 10,392 herpes zoster vaccines doses in Australia. Vaccine. 2024. PMID: 38677792. doi:10.1016/j.vaccine.2024.03.066
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。